At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 139 enrolled

Drug / intervention

Cernilton +1 moredrug

Likely dose

Cernilton 23 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00919893

NCT00919893Phase 3Completed

Compare CT.gov

Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-chronic Pelvic Pain Syndrome

University of Giessen·interventional·Posted Jun 12, 2009·Updated Nov 20, 2020

In Brief

A Phase 3 clinical trial evaluating Cernilton and Placebo for Chronic Prostatitis and Chronic Pelvic Pain Syndrome. Completed, enrolled 139 participants across 1 site.

Detailed Summary

In this placebo controlled study the safety and efficacy of Cernilton, a standardized pollen extract, in men with inflammatory chronic prostatitis-chronic pelvic pain syndrome was investigated. The purpose of this study is to determine whether Cernilton is safe and effective in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsChronic Prostatitis, Chronic Pelvic Pain Syndrome

CountriesGermany

CollaboratorsStrathmann AG&Co, Hamburg, Germany, Cernelle, Ängelholm, Sweden

Timeline

Phase 3CompletedFinished

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartDec 1999

Primary CompletionJan 2004

First PostedJun 2009

TodayJul 2026

First PostedJun 12, 2009

Enrollment StartDec 1, 1999

Primary CompletionJan 1, 2004

TodayJul 2, 2026

Enrollment to primary: 4.1 yearsPosted 17.1 years ago

Interventions

Cerniltondrug

Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.

Placebodrug

Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.